By Bhanvi Satija and Marleen Kaesebier LONDON, July 21 - Novartis beat second-quarter profit forecasts and kept its 2026 ...

July 21 - Novartis' second-quarter core operating profit beat market expectations on Tuesday, helped by strong sales of ...

Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for ...

Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma ...

Novartis' CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s Lipfendra, doubling ...

Novartis AG ended Q2 on a high note as oncology offset Entresto weakness; 2026 guidance reaffirmed. Read why NVS stock is ...

Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...

Newer cancer medicines helped quarterly earnings reach $5.94 billion, while Novartis maintained its full-year guidance.

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a ...

Novartis has dropped a phase 2-stage radioligand therapy (RLT) after the candidate disappointed in the clinic. The Swiss pharma had been evaluating the gastrin-releasing peptide receptor ...

ZURICH, July 6 (Reuters) - Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to close in the second half ...

Novartis India Q1 profit rose 16% to Rs 32.2 crore and revenue climbed 18%, though shares fell 3%; read the key numbers.